Data API Builder helps developers expose database objects through REST and GraphQL without building extensive custom data access code. Steve Jones' Visual Studio Live! San Diego 2026 session will show ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

This crash course on how to build a RESTful API with Spring Boot teaches everything you need to know to immediately develop enterprise-grade microservices in Java. In just 90 minutes you'll learn how ...

Google API keys for services like Maps embedded in accessible client-side code could be used to authenticate to the Gemini AI assistant and access private data. Researchers found nearly 3,000 such ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eikon Therapeutics increased the ...

Eikon Therapeutics shares were down 6%, at $16.90, in the stock's first day of trade on the Nasdaq Global Select Market. Shares of the clinical-stage biopharmaceutical company began trading midday ...

Despite progress made in cancer immunotherapy, some patients don’t respond to these treatments or they stop responding after a period of time. Eikon Therapeutics’ lead drug candidate could address ...

Oncology-focused Eikon Therapeutics Inc. set the terms of its IPO Jan. 28, selling 17.648 million shares at a price range between $16 to $18 per share. At the top of the range, the Millbrae, ...

Eikon ‍Therapeutics (EIKN), a cancer drug developer led by Merck (MRK) veteran Roger Perlmutter, has filed for its U.S. IPO seeking a valuation of up to $908M with roughly 17.6M shares on offer. The ...

After announcing plans to go public at the top of the year, Eikon Therapeutics has now revealed the proceeds it hopes to pull in from its initial stock offering: $273.5 million. The oncology biotech ...

Jan 28 (Reuters) - Eikon ‍Therapeutics, headed ‌by Merck veteran Roger Perlmutter, is ‌targeting a valuation of up to $908.2 million in its initial public offering in the United States, as biotech ...